Concentra Group Holdings Parent, Inc. (CON)vsJohnson & Johnson (JNJ)
CON
Concentra Group Holdings Parent, Inc.
$25.32
+1.61%
HEALTHCARE · Cap: $3.60B
JNJ
Johnson & Johnson
$231.29
+0.80%
HEALTHCARE · Cap: $567.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 4217% more annual revenue ($96.36B vs $2.23B). JNJ leads profitability with a 21.8% profit margin vs 8.0%. CON trades at a lower P/E of 20.2x. CON earns a higher WallStSmart Score of 59/100 (C).
CON
Buy59
out of 100
Grade: C
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CON.
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$231.29
$95.17 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Earnings expanding 29.4% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
8.0% margin — thin
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CON
The strongest argument for CON centers on Return on Equity, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : CON
The primary concerns for CON are Profit Margin, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 5.00 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CON profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
CON is growing revenue faster at 13.7% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CON scores higher overall (59/100 vs 57/100) and 13.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Concentra Group Holdings Parent, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Concentra Group Holdings Parent, Inc. (Ticker: CON) is a dynamic diversified holding company focused on acquiring and managing businesses in high-growth sectors, including healthcare, technology, and infrastructure. With a strong commitment to operational excellence and innovation, Concentra employs its experienced leadership team to drive portfolio optimization through strategic investments and hands-on management. This proactive approach enables the company to effectively seize emerging trends and opportunities, positioning it as a compelling investment for institutional investors seeking diversification into high-potential markets.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?